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ABSTRACT
During a 2-month period in 2005, 13 laboratories participated in a surveillance study of Clostridium
difﬁcile-associated disease (CDAD) in 17 hospitals in The Netherlands. The median incidence rate of
CDAD was 16 ⁄ 10 000 patient admissions (2.2 ⁄ 10 000 patient-days) and varied from 1 to 46 ⁄ 10 000
patient admissions according to hospital. In total, 81 patients with CDAD were reported; 49 (61%)
patients had nosocomial CDAD, and 29 (36%) patients were admitted to hospital when already
suffering from diarrhoea. Two (2%) deaths were attributable to CDAD; both of these patients were
admitted with severe community-onset CDAD and were aged >80 years. Among 64 toxinogenic
isolates, ten (16%) belonged to PCR ribotype 027 and ten (16%) to PCR ribotype 014. Type 027 was
identiﬁed in ten patients from one hospital during an unrecognised outbreak. Toxinotyping of the 64
isolates revealed the presence of six different toxinogenic types, with 41 (64%) isolates of toxinotype 0,
ten (16%) isolates of toxinotype III, and nine (14%) isolates of toxinotype V. Of the 64 toxinogenic
isolates, seven (11%) had a 39-bp deletion in the tcdC gene, 11 (17%) had an 18-bp deletion, and one
(1%) had a deletion of c. 44 bp. Genes for binary toxin were present in 21 (33%) of the 64 toxinogenic
isolates, mainly associated with toxinotypes III and V. It was concluded that the median CDAD
incidence rate of 16 ⁄ 10 000 patient admissions in The Netherlands is considerably lower than that in
Canada and the USA, and that the emerging type 027 can spread unnoticed. The high proportion (36%)
of CDAD cases with a community onset has important implications for future studies of the
epidemiology of CDAD.
Keywords Clostridium difﬁcile, epidemiology, Netherlands, PCR ribotypes, surveillance study, toxinotypes
Original Submission: 10 October 2006; Revised Submission: 9 April 2007; Accepted: 23 May 2007
Clin Microbiol Infect 2007; 13: 1058–1064
INTRODUCTION
Since the recognition of Clostridium difﬁcile as the
causative agent of pseudo-membranous colitis in
1978, this anaerobic spore-forming bacterium has
emerged as an important enteropathogen. The
spectrum of C. difﬁcile-associated disease
(CDAD) varies from mild diarrhoea to severe
colitis, and it may lead to toxic megacolon,
perforation, sepsis and death [1]. Antibiotic
exposure is considered to be the major risk-factor
for CDAD, but other predisposing factors for
CDAD have also been recognised [2,3]. Patho-
genic strains of C. difﬁcile release enterotoxin A
(TcdA; 308 kDa) and cytotoxin B (TcdB;
270 kDa), which ultimately mediate diarrhoea
and colitis. Some C. difﬁcile isolates have been
reported to produce an actin-speciﬁc ADP-ribo-
syltransferase (binary toxin), but the signiﬁcance
of this is unclear [4]. For epidemiological pur-
poses, C. difﬁcile can be divided into >150 PCR
ribotypes and 25 toxinotypes [5–8].
Since 2002, the rate and severity of CDAD has
been increasing in the USA, Canada and Europe
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because of the spread of one speciﬁc strain that
belongs to restriction enzyme analysis group BI,
pulsed-ﬁeld gel electrophoresis type NAP1, PCR
ribotype 027 and toxinotype III [9–14]. In 2005, a
European study was performed to characterise
isolates from nosocomial cases of CDAD in
hospitals of 14 countries, with three hospitals
per country [15]. The present study describes an
extension of this investigation in The Nether-
lands to 17 hospitals, with the inclusion of all
diagnosed forms of CDAD, irrespective of




A CDAD case was deﬁned as a patient with diarrhoea and a
positive laboratory assay for C. difﬁcile toxin A and ⁄or B in
stools [9]. A CDAD was classiﬁed as severe if a patient also
fulﬁlled at least one of the following criteria: (i) polynuclear
neutrophil count ‡20 000 ⁄mm3; or (ii) serum albumin concen-
tration <35 g ⁄L. Patients were classiﬁed into three categories,
based on the severity of the underlying disease, according to
the McCabe score: no fatal disease (A); fatal disease in the
following 5 years (B); or fatal disease in the following year (C)
[16]. A case was considered to be nosocomial if diarrhoea
started ‡48 h after admission [9]. Community-onset CDAD
was deﬁned as a patient admitted with diarrhoea, or if the
diarrhoea started within 2 days of admission. Only one
episode ⁄patient was included in the survey. An episode was
designated as a recurrence when it occurred within 8 weeks of
the onset of a previous episode [9].
Design of the study
In January 2005, microbiologists in The Netherlands were
invited to participate in a prospective laboratory-based study
of the incidence of CDAD in the period 1 May to 1 July 2005.
Thirteen microbiologists employed by 17 hospitals (including
six small hospitals) agreed to participate and informed their
associated clinicians and infection control practitioners.
Laboratories applied their own algorithms and no recommen-
dations were given concerning speciﬁc toxin faeces tests. All
patients diagnosed with CDAD during the study period were
included. Information was recorded concerning the number of
beds, patient-days and number of admissions, and the
laboratory tests used to diagnose CDAD. Each participating
microbiologist used a standardised questionnaire to collect
information concerning each patient’s age and gender, the
ward in which CDAD was diagnosed, the duration of
diarrhoea and consistency of faeces, the presence of abdom-
inal pain or fever (‡38C), maximal white blood cell count,
serum albumin concentration, risk-factors, antibiotic treatment
in the month preceding a positive test, and treatment
outcome. Faecal samples of patients with CDAD were stored
at )20C before being sent to the Reference Laboratory at
Leiden University Medical Center for culture and strain
characterisation.
Culture and identiﬁcation of C. difﬁcile isolates
Culture of faecal samples for C. difﬁcile was performed at the
Reference Laboratory using C. difﬁcile selective agar (CLO-
medium; bioMe´rieux, Marcy l’Etoile, France) with and without
ethanol shock pretreatment [17]. C. difﬁcile was identiﬁed
phenotypically by production of L-proline-aminopeptidase
and hydrolysis of aesculin [18]. Isolates of C. difﬁcile were
characterised further by PCR.
Strain characterisation
All isolates were identiﬁed genetically as C. difﬁcile by an
in-house PCR to detect the presence of the gluD gene, encoding
the glutamate dehydrogenase speciﬁc for C. difﬁcile, using
forward primer 5¢-GTCTTGGATGGTTGATGAGTAC and re-
verse primer 5¢-TTCCTAATTTAGCAGCAGCTTC. For detec-
tion of tcdA, primers NKV011 and NK9 were used as described
by Kato et al. [19]. The tcdB proﬁle was veriﬁed with primers
NK104 and NK105 [20]. The presence of deletions in tcdC was
investigated using an in-house PCR with forward primer
5¢-CATATCCTTTCTTCTCCTCTTC and reverse primer
5¢-AATTGTCTGATGCTGAACC, yielding an expected ampli-
con size (without a deletion) of 159 bp [21]. The presence of the
genes for the binary toxin, cdtA and cdtB, was investigated as
described by Stubbs et al. [22]. PCR ribotyping was performed
according to the methods described by Bidet et al. [6].
Toxinotyping was performed as described by Rupnik et al.
[8], using the data for two fragments, B1 and A3.
RESULTS
Participating hospitals
The participating hospitals were distributed
throughout The Netherlands. Of 17 participating
hospitals, six were university-afﬁliated centres
(Table 1, laboratories 1–5 and 13) and 11 were
community hospitals (laboratories 6–12). The
laboratories of two participating hospitals also
functioned as public health laboratories (labora-
tories 6 and 11). Two district laboratories pro-
vided microbiological services for several small
community hospitals, covering 600 beds in two
hospitals and 1730 beds in four hospitals, respec-
tively (laboratories 8 and 9).
Diagnostic methods
Laboratories using direct assays to detect the
presence of C. difﬁcile toxins in faecal samples
used either cytotoxicity assays (laboratories 3, 4, 6
and 9–11) or enzyme immunoassays (n = 7;
laboratories 1, 2, 5, 7, 9, 12 and 13). One laboratory
performedboth types of assay (laboratory 9).Of the
13 laboratories, six cultured C. difﬁcile from faecal
samples routinely (laboratories 1, 2, 5, 8, 10 and 13).
Assays applied to cultured isolates to recognise
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toxin production included cytotoxicity tests (labo-
ratory 10), enzyme immunoassays (laboratories 1,
2 and 8) or PCR (laboratory 13).
Incidence of CDAD
The number of CDAD cases during the study
period varied from one to 13 cases ⁄ laboratory.
The overall incidence (median) rate of CDAD was
16 ⁄ 10 000 patient admissions, and varied from
one to 46 ⁄ 10 000 admissions according to hospital
(Table 1). There was no correlation between the
incidence of CDAD and the number of hospital
beds.
Characteristics of patients with CDAD
In total, 91 completed questionnaires were
obtained. Ten patients were excluded from
the analysis: three were considered to be asymp-
tomatic carriers; incomplete data were obtained
from one patient; and six patients yielded non-
toxinogenic isolates from toxin-negative faeces
(hospital A). The patient characteristics are sum-
marised in Table 2. The highest incidence of
CDAD (58%) was found in patients aged
>65 years. An estimated fatal underlying disease
was present in 40 (50%) of all patients with
CDAD (McCabe B ⁄C; Table 2). Of 81 patients
with CDAD, 20% experienced it as a recurrence.
Of these 81 patients, 29 (36%) were admitted to
the hospital with community-onset diarrhoea. Of
this group, 13 (45%) had been hospitalised in the
previous month and ﬁve (46%) of these experi-
enced CDAD as a recurrence. Data for the
remaining 3% patients were not available.
The majority (53%) of patients with CDAD
were hospitalised in a general medical ward,
while 26% were in a surgical department and
10% were in an intensive care unit. Patients with
Table 1. Incidence of Clostridium difﬁcile-associated disease (CDAD) in 13 participating laboratories and general





















1 653 46 6 11 5 2 (0, V)
2 1002 37 4 13 5 3 (0, III, VI)
3 662 16 2 3 3 1 (0)
4 815 17 3 6 5 3 (0, V, XII)
5 1300 14 2 4 3 2 (0, V)
6 1070 13 3 7 4 1 (0)
7 653 14 2 3 3 2 (0, V)
8a 600 3 <1 1 1 1 (0)
9b 1730 2 <1 4 4 1 (0)
10 1368 4 1 3 3 1 (V)
11 697 5 1 2 2 1 (0)
12 1100 14 2 6 5 3 (0, IV, V)
13 882 12 2 4 4 2 (0, XII)
aProvided microbiological services for two small hospitals.
bProvided microbiological services for four small hospitals.
Table 2. Characteristics of 81 patients with Clostridium
difﬁcile-associated disease
















Community onset 29 (36)
Unknown 3 (3)
Length of diarrhoea
<2 days 14 (17)
2–7 days 28 (35)
>7 days 33 (41)
Unknown 6 (7)












Previous hospitalisation (1 month) 39 (48)
Cancer 10 (12)
Nasogastric tube 15 (19)
AIDS 1 (1)
Previous antibiotic use 61 (75)
aA, no fatal disease; B, fatal disease in the following 5 years; C, fatal disease in the
following year [16].
bNosocomial, development of diarrhoea ‡48 h after admission; community-onset,
development of diarrhoea outside the hospital or >48 h following admission.
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nosocomial CDAD in different departments did
not differ in terms of age, McCabe score or
duration of hospitalisation (data not shown).
The most common clinical presentation of CDAD
was as a diarrhoeal disease with liquid or loose
faeces for 2–7 days (35%) or >7 days (41%),
without abdominal pain (50%) and without fever
(67%). A severe course of CDAD was observed in
12 (15%) patients.
Of all CDAD patients, 48% had been hospita-
lised in the previous month. Antibiotic use in the
preceding month was recorded for 61 (75%) of the
81 patients. The most frequently prescribed anti-
biotics were b-lactam antibiotics (47% of treated
patients) and ﬂuoroquinolones (12% of treated
patients).
Treatment and outcome
Of 75 patients with CDAD for whom treatment
information was available, 60 (69%) required
speciﬁc treatment: 51 were treated with metroni-
dazole alone; ﬁve received metronidazole
followed by vancomycin; and four were treated
with vancomycin alone. Seven (8%) patients died
during the study period, with CDAD considered
to be the cause of death for two patients. One of
these was a male aged 83 years with diarrhoea,
which was present for more than a month before
admission. The patient was not treated with
antibiotics during the previous month and had
none of the known risk-factors. He was not treated
speciﬁcally for CDAD and died 5 days after
admission because of respiratory insufﬁciency.
Typing of the C. difﬁcile isolate revealed that it
belonged to the toxin-producing PCR ribotype
001. The second death was of a female, aged
86 years, with diarrhoea for >7 days before admis-
sion. This patient died within a week of admission
because of cardiac insufﬁciency. Typing of the
C. difﬁcile isolate revealed that it belonged to the
toxin-producing PCR ribotype 078, with a 39-bp
deletion in the tcdC gene.
C. difﬁcile isolates
Faecal samples from 81 patients were included in
the analysis. Of these, 67 contained C. difﬁcile, as
determined by a PCR result positive for the
presence of gluD. Of 67 C. difﬁcile isolates, 64
were positive for tcdA and tcdB (Table 3); of these,
45 (70%) harboured an intact tcdC gene, seven
(11%) had a 39-bp deletion in the tcdC gene, and
11 (17%) had an 18-bp deletion, with ten of the
latter isolates belonging to PCR ribotype 027 ⁄ tox-
inotype III (Table 3). One (2%) isolate had a
deletion of c. 44 bp, which has not been described
previously (toxinotype 0; Table 3). Of the 64
isolates, 19 (30%) contained both binary toxin
genes, whereas two (3%) contained only the cdtA
binary toxin gene (Table 1, laboratories 4 and 12).
PCR ribotyping and toxinotyping
Among the 67 isolates, 28 different PCR ribotypes
were recognised (Table 1). Among the 64 toxino-
genic isolates, 41 (64%) were of toxinotype 0
(Table 3). The most frequently occurring PCR
ribotypes were 027 (16%) and 014 (16%). Ten
(48%) of the 21 binary toxin-positive isolates
belonged to PCR ribotype 027 ⁄ toxinotype III, and
nine (43%) belonged to toxinotype V (Table 3).
The latter isolates were obtained from six differ-
ent hospitals (Table 1).
DISCUSSION
This study revealed a mean incidence of CDAD in
The Netherlands of 16 ⁄ 10 000 patient admissions
(2.2 ⁄ 10 000 bed-days), which is comparable to the
results of a European study performed in 2002
[23]. The incidence rate in the participating









No. of isolates with
binary toxin genes
(cdtA ⁄ cdtB)
No. of isolates with deletions in tcdC (bp)
Intact D 18 bp D 39 bp D >39 bp
0 41 21 41 1 cdtA and cdtB 37 1 2 1
III 10 1 10 10 cdtA and cdtB 0 10 0 0
IV 1 1 1 1 cdtA and cdtB 1 0 0 0
V 9 3 9 7 cdtA and cdtB
2 cdtA
4 0 5 0
VI 1 1 1 0 1 0 0 0
XII 2 2 2 0 2 0 0 0
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hospitals was comparable to the pre-outbreak
incidence in eight hospitals in The Netherlands
that were affected by PCR ribotype 027 during
2006. Interestingly, one outbreak hospital (no. 2)
also participated in the present surveillance study
and had a higher incidence level than the other
hospitals [14].
The incidence of CDAD as a nosocomial
disease was 13 ⁄ 10 000 patient admissions. This
low incidence does not reﬂect the use of inade-
quate diagnostic tests, since all participating
laboratories used a toxin assay, and 46% applied
the cytotoxin test to faecal samples. The observa-
tion that 16% of positive faecal samples were
culture-negative reﬂects the low concordance of
enzyme immunoassays with culture of c. 60%
[24]. Recent data from studies in the USA and
Canada have demonstrated a much higher inci-
dence of CDAD of 100–450 ⁄ 10 000 admissions
among hospitalised patients, which has been
associated with the emergence of infections
caused by the hypervirulent PCR ribotype 027
strain [10–13]. In Quebec, Canada, where type 027
is endemic, a survey of 39 hospitals revealed a
mean CDAD incidence rate of 19 ⁄ 10 000 bed-
days, which is nearly ten-fold higher than the
CDAD incidence rate in The Netherlands [25].
C. difﬁcile is often deﬁned as a nosocomial
pathogen. However, it is widely disseminated in
the environment, and has been isolated from soil,
water and the faeces of many wild, domestic and
farmed animals [5]. Surprisingly, 31 (36%) of
all patients with CDAD were admitted to the
hospital with diarrhoea, or developed diarrhoea
within 2 days of admission. However, 13 (33%)
patients had been hospitalised in the previous
month, indicating a community onset with
hospital association. Two (6%) of these 31
patients died, with CDAD as an attributable
cause of death. These two cases represent
community-acquired CDAD with a fatal outcome.
This observation is in agreement with CDC
reports that mention severe community-onset
CDAD in US populations considered previously
to be at low risk [26].
Since the recognition of outbreaks caused by
type 027 in at least 20 healthcare facilities in The
Netherlands, several recommendations and guide-
lines have been published by the Netherlands
Centre for Infectious Disease Control (National
Institute for Public Health and the Environment,
Bilthoven) for use by clinicians and microbio-
logists. Most laboratories apply the ‘3-day rule’
and use the deﬁnitions suggested by the Euro-
pean CDC [9] to recognise and differentiate
hospital-acquired and community-acquired
CDAD. During a 3-month study using this algo-
rithm at four university laboratories, a 30%
increase in the number of CDAD patients
diagnosed was recorded [24].
In the present study, 28 different PCR ribotypes
were found in 17 hospitals. This represents 15%
of the 109 hospitals in The Netherlands. The PCR
ribotypes were distributed equally among all
hospitals, except for PCR ribotype 027, which
was restricted to a single hospital. The common-
est PCR ribotype was 014 (16%), found in six
different hospitals. These results agree with the
results of a study performed during 2005 in
Hungary, in which 24.8% of isolates belonged to
PCR ribotype 014 [27]. However, in 2001, PCR
ribotype 087 accounted for 39% of 165 C. difﬁcile
isolates in Hungary [28], demonstrating clearly
that the incidence of PCR ribotypes can change
over time.
All isolates in the present surveillance study
contained genes encoding toxins A and B, and
no toxinotype VIII isolates were found. Although
A– ⁄B+ isolates were not detected, an outbreak
was recognised in February 2006 in a hospital in
The Netherlands, which simultaneously experi-
enced an outbreak caused by PCR ribotype 027
[14].
In the present study, one hospital experienced
an outbreak caused by PCR ribotype 027, toxino-
type III. C. difﬁcile type 027 isolates have an 18-bp
deletion in the tcdC gene. This gene is thought to
be a negative regulator of TcdA and TcdB
production, and it has been reported that these
type 027 isolates produce TcdA and TcdB in
considerably greater quantities than toxinotype 0
isolates [29]. Deletions in tcdC are frequently
present in toxinogenic isolates [21], and the
present study found that 30% of toxinogenic
isolates had a deletion of 18 bp or 39 bp, with one
strain having a previously unreported deletion of
44 bp in tcdC. It is possible that different deletions
in tcdC cause different functionality and affect
toxin production differently. Interestingly, the
isolates from the two patients who died did not
belong to type 027, but contained deletions in the
toxin regulator gene tcdC. In this study, toxino-
type 0 was the most frequently isolated type
(46%), followed by types III, IV, V, VI and XII,
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which is similar to the results of previous studies
encompassing isolates from collections in Europe
and Asia [8]. Binary toxin genes were detected in
33% of toxinogenic isolates, mainly in association
with toxinotypes III and V. This percentage is
higher than that reported previously and can be
explained by differences in the geographical
distribution of different clones [30].
In summary, the incidence of CDAD in The
Netherlands varied considerably in individual
hospitals, but was considerably lower than the
incidences reported in the USA and Canada,
independent of the occurrence of PCR ribotype
type 027. The ﬁnding that 36% of all patients
diagnosed with CDAD have a community onset
or a community association merits further studies
to determine its signiﬁcance.
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